SCHEMBL20595706

SCHEMBL20595706

CCOC(=O)CNC(=O)NC(Cc1ccc(Cl)cc1Cl)C(OC)OC

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
HTT P42858 3/20 0.42
GAA P10253 2/20 0.42
NPC1 O15118 1/20 0.41
KDM4E B2RXH2 3/20 0.39
ALDH1A1 P00352 3/20 0.39
PPID Q08752 2/20 0.39
TDP1 Q9NUW8 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
THRB P10828 1/20 0.37
IDO1 P14902 1/20 0.37
PPIB P23284 1/20 0.37
PPIA P62937 1/20 0.37
PPIG Q13427 1/20 0.37
HDAC8 Q9BY41 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23419468 1.00 CYP3A4 (0.43) CYP3A4CYP2C9HTTGAANPC1
SCHEMBL13190848 0.78 PPID (0.56) CYP3A4CYP2C9HTTGAANPC1
SCHEMBL8744815 0.74 GAA (0.56) HTTGAANPC1KDM4EALDH1A1
SCHEMBL20595707 0.74 HTT (0.44) CYP3A4CYP2C9HTTGAANPC1
SCHEMBL4287499 0.73 ALDH1A1 (0.52) CYP3A4CYP2C9HTTGAAKDM4E
SCHEMBL13283749 0.70 CYP3A4 (0.50) CYP3A4CYP2C9HTTGAANPC1
SCHEMBL2721817 0.70 CYP3A4 (0.50) CYP3A4CYP2C9HTTGAANPC1
SCHEMBL2721815 0.70 CYP3A4 (0.50) CYP3A4CYP2C9HTTGAANPC1
SCHEMBL9978726 0.70 CYP3A4 (0.61) CYP3A4CYP2C9GAAALDH1A1MEN1
SCHEMBL707398 0.69 KMT2A (0.57) CYP3A4CYP2C9HTTGAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them UNIVERSITY OF WASHINGTON (US) 2023-02-21 US disclosed
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON 2021-05-27 US disclosed
WO-2018237349-A1 INHIBITORS OF TYPED 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON (US) 2018-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them AARS1, EMG1, GARS1 CYP3A4 3715/4885CYP2C9 4091/4885HTT 1480/4885
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM AARS1, GARS1, MTR CYP3A4 3736/4885CYP2C9 3990/4885HTT 1309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.